Inflammasome sensor proteins and IL-1 blocking therapies are expanding in humans [61,62,63,64,65], and, as a result, we will be able to more adequately control cancers that have activated NLRP or secrete IL-1β than those cancers that do not. The gene discussed is PROS1; the disease is cancer.